![]() |
|
Stopping TKI therapy in Chronic Myeloid Leukemia
|
![]() |
Treating pediatric Chronic Myeloid Leukemia - an update
|
We are pleased to make available a new series of presentations on various aspects of CML management that were first presented at the 22nd Meeting of the European Hematology Association (EHA) in Madrid in 2017. Modules currently featured include; how to treat CML in 2017, factors affecting clinical decision making in relapsed and refractory CP-CML patients and treatment outcomes of bosutinib from real-world data.
We are very grateful for the support of Brandcast media to produce these webstreams. | |||||
![]() |
|
How to treat CML in 2017?
This presentation is adapted from the one presented during the CML educational session at EHA. It lasts around 30 minutes. |
![]() |
|
Factors affecting clinical decision making in refractory and relapsed CP-CML patients
This presentation is adapted from one given during the industry sponsored symposium at EHA. |
![]() |
|
This presentation is adapted from one given during the industry sponsored symposium at EHA. |
We are pleased to make available a new series of presentations on modern diagnostics in CML that were first presented at the 'Clinical Symposium on Modern Diagnostics' during the 18th John Goldman Conference on CML in Houston in 2016. Modules currently featured include; The role of cytogenetic monitoring in CML management, Molecular monitoring in CML, Mutation screening and Biomarkers and response monitoring beyond PCR.
![]() |
The role of cytogenetic monitoring in CML management
|
|